Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel monoclonal antibody therapeutics for inflammatory and immunological indications. Spun out of Paragon Therapeutics, the company focuses on chronic skin diseases such as plaque psoriasis and psoriatic arthritis. Its lead pipeline candidates include ORKA-001, an IL-23 inhibitor, and ORKA-002, an IL-17A/F inhibitor. Both assets are engineered with extended half-life technology designed to allow for infrequent dosing intervals of once or twice per year. Operating primarily in the United States, Oruka aims to provide patients with highly efficacious biologic treatments that significantly reduce the burden of frequent administration compared to conventional therapies.
